Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus

Erenumab is the first human monoclonal antibody to be approved as a selective therapy for migraine prophylaxis in adults. This study assessed, in a real-world setting, the efficacy of erenumab and its impact on the quality of life (QoL) of Cypriot migraine patients who had failed several treatments...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andria Tziakouri, Haritini Tsangari, Costas Michaelides
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	erenumab chronic migraine quality of life MSQ V2.1 Cyprus treatment failure Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/ca93a83005dd4a5b94031ceab35804ff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ca93a83005dd4a5b94031ceab35804ff
record_format	dspace
spelling	oai:doaj.org-article:ca93a83005dd4a5b94031ceab35804ff2021-11-05T23:36:54ZAssessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus1664-229510.3389/fneur.2021.687697https://doaj.org/article/ca93a83005dd4a5b94031ceab35804ff2021-07-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fneur.2021.687697/fullhttps://doaj.org/toc/1664-2295Erenumab is the first human monoclonal antibody to be approved as a selective therapy for migraine prophylaxis in adults. This study assessed, in a real-world setting, the efficacy of erenumab and its impact on the quality of life (QoL) of Cypriot migraine patients who had failed several treatments in the past. Erenumab was prescribed as a stand-alone or as an add-on therapy to 16 patients with chronic migraine. The first component of the study examined migraine parameters before and after erenumab therapy and included an interim 3-month subjective assessment. In the second component, the patients were asked to complete the validated Migraine-Specific Quality-of-Life Questionnaire—Version 2.1 (MSQ V2.1) during the last month of their individual treatment as a measure of the QoL. The results showed a statistically significant improvement in almost all migraine parameters following erenumab treatment. In the 3-month-interval assessment, 81.3% of the patients reported an improvement in their mental well-being, anxiety, and depression levels, with more than 80% of the patients reporting an improvement in almost all assessed migraine parameters. MSQ V2.1 indicated a good health status in all three domains (mean values > 60 on a scale 0–100), with the “role function preventative” domain having the highest health scores (85). Over a period of 6 months, erenumab was safe, well-tolerated, and effective in preventing migraine symptoms and improving HR-QoL. We conclude that this novel medication, which is not yet part of the national formulary in Cyprus, may be a cost-effective solution in reducing the disease burden of chronic migraine.Andria TziakouriHaritini TsangariCostas MichaelidesCostas MichaelidesFrontiers Media S.A.articleerenumabchronic migrainequality of lifeMSQ V2.1Cyprustreatment failureNeurology. Diseases of the nervous systemRC346-429ENFrontiers in Neurology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	erenumab chronic migraine quality of life MSQ V2.1 Cyprus treatment failure Neurology. Diseases of the nervous system RC346-429
spellingShingle	erenumab chronic migraine quality of life MSQ V2.1 Cyprus treatment failure Neurology. Diseases of the nervous system RC346-429 Andria Tziakouri Haritini Tsangari Costas Michaelides Costas Michaelides Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus
description	Erenumab is the first human monoclonal antibody to be approved as a selective therapy for migraine prophylaxis in adults. This study assessed, in a real-world setting, the efficacy of erenumab and its impact on the quality of life (QoL) of Cypriot migraine patients who had failed several treatments in the past. Erenumab was prescribed as a stand-alone or as an add-on therapy to 16 patients with chronic migraine. The first component of the study examined migraine parameters before and after erenumab therapy and included an interim 3-month subjective assessment. In the second component, the patients were asked to complete the validated Migraine-Specific Quality-of-Life Questionnaire—Version 2.1 (MSQ V2.1) during the last month of their individual treatment as a measure of the QoL. The results showed a statistically significant improvement in almost all migraine parameters following erenumab treatment. In the 3-month-interval assessment, 81.3% of the patients reported an improvement in their mental well-being, anxiety, and depression levels, with more than 80% of the patients reporting an improvement in almost all assessed migraine parameters. MSQ V2.1 indicated a good health status in all three domains (mean values > 60 on a scale 0–100), with the “role function preventative” domain having the highest health scores (85). Over a period of 6 months, erenumab was safe, well-tolerated, and effective in preventing migraine symptoms and improving HR-QoL. We conclude that this novel medication, which is not yet part of the national formulary in Cyprus, may be a cost-effective solution in reducing the disease burden of chronic migraine.
format	article
author	Andria Tziakouri Haritini Tsangari Costas Michaelides Costas Michaelides
author_facet	Andria Tziakouri Haritini Tsangari Costas Michaelides Costas Michaelides
author_sort	Andria Tziakouri
title	Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus
title_short	Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus
title_full	Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus
title_fullStr	Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus
title_full_unstemmed	Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus
title_sort	assessment of the effect of erenumab on efficacy and quality-of-life parameters in a cohort of migraine patients with treatment failure in cyprus
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/ca93a83005dd4a5b94031ceab35804ff
work_keys_str_mv	AT andriatziakouri assessmentoftheeffectoferenumabonefficacyandqualityoflifeparametersinacohortofmigrainepatientswithtreatmentfailureincyprus AT haritinitsangari assessmentoftheeffectoferenumabonefficacyandqualityoflifeparametersinacohortofmigrainepatientswithtreatmentfailureincyprus AT costasmichaelides assessmentoftheeffectoferenumabonefficacyandqualityoflifeparametersinacohortofmigrainepatientswithtreatmentfailureincyprus AT costasmichaelides assessmentoftheeffectoferenumabonefficacyandqualityoflifeparametersinacohortofmigrainepatientswithtreatmentfailureincyprus
_version_	1718444008348319744

Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus

Ejemplares similares